期刊文献+

Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD 被引量:9

原文传递
导出
摘要 The pathogenesis of metabolic-associated fatty liver disease(MAFLD)is complex and thought to be dependent on multiple parallel hits on a background of genetic susceptibility.The evidence suggests that MAFLD progression is a dynamic two-way process relating to repetitive bouts of metabolic stress and inflammation interspersed with endogenous anti-inflammatory reparative responses.In MAFLD,excessive hepatic lipid accumulation causes the production of lipotoxins that induce mitochondrial dysfunction,endoplasmic reticular stress,and over production of reactive oxygen species(ROS).Models of MAFLD show marked disruption of mitochondrial function and reduced oxidative capacitance with impact on cellular processes including mitophagy,oxidative phosphorylation,and mitochondrial biogenesis.In excess,ROS modify insulin and innate immune signaling and alter the expression and activity of essential enzymes involved in lipid homeostasis.ROS can also cause direct damage to intracellular structures causing hepatocyte injury and death.In select cases,the use of anti-oxidants and ROS scavengers have been shown to diminish the proapoptopic effects of fatty acids.Given this link,endogenous anti-oxidant pathways have been a target of interest,with Nrf2 activation showing a reduction in oxidative stress and inflammation in models of MAFLD.Thyroid hormone receptorβ(THRβ)agonists and nuclear peroxisome proliferationactivated receptor(PPAR)family have also gained interest in reducing hepatic lipotoxicity and restoring hepatic function in models of MAFLD.Unfortunately,the true interplay between the clinical and molecular components of MAFLD progression remain only partly understood.Most recently,multiomics-based strategies are being adopted for hypothesis-free analysis of the molecular changes in MAFLD.Transcriptome profiling maps the unique genotype-phenotype associations in MAFLD and with various single-cell tran scriptome-based projects underway,there is hope of novel physiological insights to MAFLD progression and uncover therapeutic targets.
出处 《Journal of Clinical and Translational Hepatology》 SCIE 2022年第5期939-946,共8页 临床与转化肝病杂志(英文版)
  • 相关文献

参考文献3

二级参考文献65

  • 1Nobili V, Alkhouri N, Alisi A, Della Corte C, Fitzpatrick E, RaponiM, Dhawan A. Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr 2015; 169: 170-176 [PMID: 25506780DOI: 10.1001/jamapediatrics.2014.2702].
  • 2Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, ContrerasM, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liverdisease and nonalcoholic steatohepatitis among a largely middleagedpopulation utilizing ultrasound and liver biopsy: a prospectivestudy. Gastroenterology 2011; 140: 124-131 [PMID: 20858492DOI: 10.1053/j.gastro.2010.09.038].
  • 3Anstee QM, Targher G, Day CP. Progression of NAFLD todiabetes mellitus, cardiovascular disease or cirrhosis. Nat RevGastroenterol Hepatol 2013; 10: 330-344 [PMID: 23507799 DOI:10.1038/nrgastro.2013.41].
  • 4Vernon G, Baranova A, Younossi ZM. Systematic review: theepidemiology and natural history of non-alcoholic fatty liver diseaseand non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x].
  • 5Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histologyin obese patients undergoing bariatric surgery. J Hepatol 2006; 45:600-606 [PMID: 16899321].
  • 6Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E,Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and itsconnection with insulin resistance, dyslipidemia, atherosclerosisand coronary heart disease. Nutrients 2013; 5: 1544-1560 [PMID:23666091 DOI: 10.3390/nu5051544].
  • 7Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA,Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the secondleading etiology of liver disease among adults awaiting livertransplantation in the United States. Gastroenterology 2015; 148:547-555 [PMID: 25461851 DOI: 10.1053/j.gastro.2014.11.039].
  • 8Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, HuiJM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, WeltmanM, George J. NASH and insulin resistance: Insulin hypersecretionand specific association with the insulin resistance syndrome.Hepatology 2002; 35: 373-379 [PMID: 11826411].
  • 9Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A,Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD,Budoff MJ, Nasir K. A systematic review: burden and severity ofsubclinical cardiovascular disease among those with nonalcoholicfatty liver; should we care- Atherosclerosis 2013; 230: 258-267[PMID: 24075754 DOI: 10.1016/j.atherosclerosis.2013.07.052].
  • 10Than NN, Newsome PN. A concise review of non-alcoholicfatty liver disease. Atherosclerosis 2015; 239: 192-202 [PMID:25617860 DOI: 10.1016/j.atherosclerosis.2015.01.001].

共引文献288

同被引文献27

引证文献9

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部